Primary Immune Thrombocytopenia Clinical Trial
Official title:
Effect of DNA Methyltransferase 3A-448 G/A and 3B-149 C/T Single Nucleotide Polymorphisms on Global DNA Methylation in Primary Immune Thrombocytopenia
- To compare global DNA methylation status between ITP patients and healthy subjects .
- To determine the effect of DNMT3A −448 G/A SNP variant A allele and DNMT3B −149C/T SNP
variant T-allele on global DNA methylation in both ITP patients and healthy control
subjects.
Immune thrombocytopenia (ITP), is an immune-mediated acquired disease of adults and children
characterized by transient or persistent decrease of the platelet count and, depending upon
the degree of thrombocytopenia, increased risk of bleeding (Rodeghiero et al., 2009).
International guidelines define thrombocytopenia as a peripheral blood platelet count less
than 100 000/uL (Raj, 2017). Platelet count values between 100 000/uL and 150 000/uL are
frequently found in apparently healthy people (Adibi et al., 2007) and this threshold reduces
the concern over the mild "physiologic" thrombocytopenia associated with pregnancy (Neunert
et al., 2011).
Immune thrombocytopenia may be primary or secondary. Primary ITP is a diagnosis of exclusion.
Secondary ITP occur due to an underlying diseases/conditions. Causes of secondary ITP include
infection (CMV, Helicobacter pylori, HCV, HIV, Varicella zoster), Systemic lupus
erythematosus, Antiphospholipid syndrome, Drug-induced, Lymphoproliferative disorders, Post
bone marrow transplantation, and Post vaccination (Neunert et al., 2011).
Primary ITP is an acquired autoimmune disease causing both increased platelet destruction and
insufficient platelet production. More than one mechanism could contribute to this including
autoreactive B lymphocytes, Th1/Tc1 polarization, T-cell-mediated platelet lysis and abnormal
circulating Treg cells. Also, DNA methylation may participate in the pathophysiology of ITP
(Semple et al., 2010, Wang et al., 2011).
DNA methylation is a heritable, stable, and also reversible way of DNA modification; it can
regulate gene expression without changing the nucleotide sequences (Huiyuan et al., 2013).
DNA methylation is mediated by DNA methyltransferases (DNMTs). There are five members in DNMT
group including DNMT3A and DNMT3B (Okano et al., 1999). DNMT3A and DNMT3B catalyze de novo
methylation and it is important in the establishment of DNA methylation patterns within the
embryo and during fetal development (Sawalha, 2008).
DNA methylation status takes part in the regulation of immune response, the loss of
methylation pattern in immune cells will result in autoimmune disease by inducing aberrant
gene expression. ITP is an autoimmune disease with many immune deficiencies with abnormal DNA
methylation involved in the disease etiology (Huiyuan et al., 2013). Chen et al., 2011,
concluded that aberrant DNA methylation may take part in the pathogenesis of ITP by
quantifying the methylcytosine concentration of genomic DNA. They found hypomethylation
pattern in CD4 T cells of ITP patients.
DNMT3A, and DNMT3B DNA methyltransferases are encoded by different genes on distinct
chromosomes (Sawalha, 2008). There are many single nucleotide polymorphisms (SNPs) in DNMT3A
gene which may affect catalytic activity of the DNMT3A enzyme, including -448G/A SNP (Zhao et
al., 2012). Twenty-one polymorphisms have been identified in the DNMT3B gene including −149
C/T SNP and −579 G/T SNP (Zhang et al., 2015).
In a previous study in Assiut University Hospital (AbdelKader et al., 2018), the DNMT3A −448
G/A SNP variant A allele was significantly associated with decreased risk of primary ITP,
while, DNMT3B −149C/T SNP variant T-allele was significantly associated with nearly
double-fold increase in risk of primary ITP. However, the underlying mechanism behind this
association was not investigated. Authors recommended to study mRNA expression of DNMT genes,
enzymatic activity of DNA methyltransferases, quantification of global methylated DNA, and/or
methylation status of methylation-sensitive genes involved in primary ITP pathogenesis to
understand this association.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06466824 -
Observational Study on the Outcome of Patients With ITP Who Underwent Splenectomy After 2010
|
||
Completed |
NCT05621330 -
Efficacy and Safety of QL0911 in Adult Patients With Chronic Primary Immune Thrombocytopenia
|
Phase 3 | |
Active, not recruiting |
NCT04278924 -
A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia
|
Phase 2 | |
Recruiting |
NCT06148389 -
The Safety and Tolerability of STSA-1301 Subcutaneous Injection in Healthy Subjects
|
Phase 1 | |
Active, not recruiting |
NCT04812925 -
A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
|
Phase 3 | |
Recruiting |
NCT06107582 -
Longitudinal Cohort of Pediatric Primary Immune Thrombocytopenia (ITP)
|
||
Recruiting |
NCT05371743 -
Plasma microRNA Levels and Some Cytokines Expression in Patients With ITP Primary Immune Thrombocytopenic Purpura (ITP)
|
||
Not yet recruiting |
NCT05311930 -
Efficacy and Safety of TPO Receptor Agonists in the Treatment of Elderly ITP Patients
|
Phase 4 | |
Not yet recruiting |
NCT05333861 -
An Observational, Multicenter Study to Evaluate the Safety and Effectiveness of Hetrombopag in Patients With ITP or AA
|
||
Completed |
NCT03102593 -
A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With ITP
|
Phase 2 | |
Completed |
NCT06071520 -
Andalusian Experience in the Use of Fostamatinib in Patients With ITP. FOSTASUR Study
|
||
Recruiting |
NCT04949009 -
Avatrombopag in the Treatment of Primary Immune Thrombocytopenia(ITP)
|
||
Terminated |
NCT04224688 -
A Study to Assess the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)
|
Phase 3 | |
Active, not recruiting |
NCT04225156 -
A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).
|
Phase 3 | |
Completed |
NCT05551624 -
Evaluation of the Effect in Platelet Count of Atorvastatin and N-acetyl Cysteine
|
Early Phase 1 | |
Recruiting |
NCT05422365 -
Intravenous Immunoglobulin (IVIG, Bioven) Efficacy and Safety in Chronic Primary Immune Thrombocytopenia (ITP) in Adults
|
Phase 3 | |
Terminated |
NCT03275740 -
A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347
|
Phase 1 | |
Terminated |
NCT04596995 -
A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)
|
Phase 3 | |
Terminated |
NCT04200456 -
A Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)
|
Phase 3 | |
Recruiting |
NCT05653219 -
A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids
|
Phase 3 |